DaVita Inc. $DVA Shares Bought by Northwestern Mutual Wealth Management Co.

Northwestern Mutual Wealth Management Co. grew its stake in shares of DaVita Inc. (NYSE:DVA) by 420.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 8,967 shares of the company’s stock after purchasing an additional 7,243 shares during the quarter. Northwestern Mutual Wealth Management Co.’s holdings in DaVita were worth $1,019,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Elevation Wealth Partners LLC increased its holdings in shares of DaVita by 147.3% in the 4th quarter. Elevation Wealth Partners LLC now owns 277 shares of the company’s stock valued at $31,000 after acquiring an additional 165 shares during the period. Canada Pension Plan Investment Board acquired a new position in shares of DaVita in the 2nd quarter valued at $43,000. iSAM Funds UK Ltd acquired a new position in shares of DaVita in the 3rd quarter valued at $46,000. Stance Capital LLC acquired a new position in shares of DaVita in the 3rd quarter valued at $47,000. Finally, Camelot Portfolios LLC purchased a new position in DaVita in the 4th quarter valued at $57,000. Institutional investors and hedge funds own 90.12% of the company’s stock.

Insider Activity

In other news, CFO Joel Ackerman sold 51,471 shares of DaVita stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $192.10, for a total transaction of $9,887,579.10. Following the completion of the transaction, the chief financial officer owned 132,434 shares of the company’s stock, valued at $25,440,571.40. The trade was a 27.99% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 1.50% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of research firms recently weighed in on DVA. UBS Group lifted their price objective on shares of DaVita from $190.00 to $235.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Barclays lifted their price objective on shares of DaVita from $158.00 to $194.00 and gave the company an “equal weight” rating in a research report on Thursday, May 7th. Zacks Research upgraded shares of DaVita from a “hold” rating to a “strong-buy” rating in a research report on Thursday, May 7th. Truist Financial lifted their price objective on shares of DaVita from $158.00 to $205.00 and gave the company a “hold” rating in a research report on Friday, May 8th. Finally, Wall Street Zen upgraded shares of DaVita from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $199.17.

DaVita Stock Up 0.1%

NYSE:DVA opened at $192.28 on Monday. The company has a market capitalization of $12.34 billion, a PE ratio of 17.84, a price-to-earnings-growth ratio of 0.63 and a beta of 0.91. DaVita Inc. has a 52-week low of $101.00 and a 52-week high of $202.69. The stock has a fifty day simple moving average of $171.47 and a 200-day simple moving average of $143.36.

DaVita (NYSE:DVA) last released its quarterly earnings results on Tuesday, May 5th. The company reported $2.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.33 by $0.54. The business had revenue of $3.42 billion during the quarter, compared to the consensus estimate of $3.36 billion. DaVita had a negative return on equity of 270.37% and a net margin of 5.65%.The business’s revenue was up 6.0% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.00 EPS. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. As a group, equities analysts anticipate that DaVita Inc. will post 15.07 earnings per share for the current year.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.